News & Updates

Patients with hepatitis delta virus (HDV) show increased virologic and biochemical responses with longer bulevirtide (BLV) treatment for over 96 weeks, with no new safety concerns, as shown in a study presented at CROI 2024.

Among patients with mild-to-moderate COVID-19, viral rebound and symptom rebound occur frequently following a standard 5-day course of treatment with either VV116 or nirmatrelvir-ritonavir, as shown in a study from China.

New drug applications approved by US FDA as of 1-15 March 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

A substantial number of plasma samples from immunocompetent people who had SARS-CoV-2 infection more than a year ago appears to contain detectable viral antigens.

Streptococcus anginosus induces gastric inflammation, atrophy, and tumorigenesis in mice, researchers from the Chinese University of Hong Kong (CUHK) have reported.

Twice-daily treatment with bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) resulted in high viral suppression among people with HIV and tuberculosis (TB) who were on rifampicin-based therapy, according to the INSIGHT* trial presented at CROI 2024.

Infections associated with spinal implants following paediatric spine deformity surgery can be treated without removing the hardware in some patients, a study has shown. Early presentation and recognition contribute to better retention rates and are associated with certain organisms.